Traders should monitor future sales trends of JORNAY PM in upcoming earnings reports to assess whether the campaign translates into measurable revenue growth. No immediate financial impact is expected.
COLL drugs
COLL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 3 $39.99entry
- T+1 · 9mo ago −0.95%α −1.71% · $39.61
- T+5 · 8mo ago −8.45%α −7.97% · $36.61
- T+20 · 8mo ago −17.30%α −12.90% · $33.07
- T+60 · 6mo ago −15.78%α −26.10% · $33.68
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Collegium Pharmaceutical announced a partnership with Paris Hilton on a public awareness campaign called 'Embrace Your Sparkle' to reduce stigma and encourage dialogue around adult ADHD. The campaign highlights Hilton's personal experience managing ADHD with JORNAY PM, Collegium's evening-dosed methylphenidate product indicated for ADHD in patients 6 years and older.
Key Facts
- Collegium Pharmaceutical partnered with Paris Hilton on an ADHD awareness campaign called 'Embrace Your Sparkle'.
- The campaign promotes open dialogue about ADHD, particularly in adults, and emphasizes individualized treatment plans.
- Paris Hilton shares her personal ADHD journey and use of JORNAY PM (methylphenidate HCl) as part of her treatment regimen.
- JORNAY PM is an extended-release CNS stimulant taken in the evening to provide symptom control from morning through early evening.
- No financial terms, revenue impact, or sales data were disclosed in the press release.
Financial Impact
No quantifiable financial impact disclosed; potential indirect benefit to JORNAY PM brand awareness.
Risk Factors
- Public campaigns involving celebrities carry reputational risk if perceived as exploitative or if safety concerns arise with the promoted product.
- JORNAY PM is a Schedule II controlled substance with risks of abuse, dependence, and serious cardiovascular or psychiatric side effects, which may limit prescribing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248249 |
Track record
24 reports on COLL
1 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +0.28% at T+1 after the Aug 13, 2026 report. 1 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
- Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
- Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers